boehringer ingelheim glp-1 dual-acting obesity shot hits mark in Phase 3 trial Boehringer Ingelheim advances triple-agonist obesity
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14



























